We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+20.47%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$239M
AUM Growth
+$36M
Cap. Flow
+$7.18M
Cap. Flow %
3%
Top 10 Hldgs %
37.89%
Holding
60
New
11
Increased
16
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
ASRT
Assertio
ASRT
+$5.63M
2
RLYP
RELYPSA INC COM
RLYP
+$4.74M
3
SAGE
Sage Therapeutics
SAGE
+$3.96M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$3.82M
5
BPMC
Blueprint Medicines
BPMC
+$3.26M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$11.8M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$6.24M
3
CEMP
Cempra, Inc.
CEMP
+$4.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.56M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 87.84%
2 Miscellaneous 12.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
1
Ultragenyx Pharmaceutical
RARE
$2.59B
$12.3M 5.16%
110,000
– –
AXGN icon
2
Axogen
AXGN
$2.78B
$10.6M 4.43%
2,120,000
– –
KYNB
3
Kyntra Bio
KYNB
$32.4M
$9.9M 4.14%
13,000
– –
GERN icon
4
Geron
GERN
$983M
$8.83M 3.69%
1,825,000
– –
GNMX
5
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8.37M 3.5%
1,390,000
+331,600
+31% +$2.25M
HROW icon
6
Harrow
HROW
$1.44B
$8.35M 3.49%
1,205,000
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.25M 3.45%
105,000
– –
ARIA
8
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$8.19M 3.42%
1,310,000
– –
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$7.54M 3.15%
85,000
+11,800
+16% +$932K
BPMC
10
DELISTED
Blueprint Medicines
BPMC
$7.24M 3.03%
275,000
+145,000
+112% +$3.26M
TVRD
11
Tvardi Therapeutics
TVRD
$24M
$7.2M 3.01%
11,861
+333
+3% +$183K
CDXS icon
12
Codexis
CDXS
$182M
$6.77M 2.83%
1,600,000
-20,000
-1% -$73.2K
TVTX icon
13
Travere Therapeutics
TVTX
$6.36B
$6.66M 2.78%
345,000
-25,000
-7% -$499K
RLYP
14
DELISTED
RELYPSA INC COM
RLYP
$6.24M 2.61%
+220,000
New +$4.74M
CEMP
15
DELISTED
Cempra, Inc.
CEMP
$6.23M 2.6%
200,000
-160,000
-44% -$4.45M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$5.83M 2.44%
100,000
+80,000
+400% +$3.96M
SUPN icon
17
Supernus Pharmaceuticals
SUPN
$2.57B
$5.64M 2.36%
420,000
-40,000
-9% -$619K
ASRT
18
DELISTED
Assertio
ASRT
$5.44M 2.27%
+5,000
New +$5.63M
ADMS
19
DELISTED
Adamas Pharmaceuticals
ADMS
$5.38M 2.25%
190,000
+24,300
+15% +$409K
AMAG
20
DELISTED
AMAG Pharmaceuticals
AMAG
$4.53M 1.89%
150,000
-50,000
-25% -$1.62M
TNXP icon
21
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– –
AVGR
22
DELISTED
Avinger, Inc. Common Stock
AVGR
$4.32M 1.8%
2
+1
+100% +$2.09M
AFMD
23
DELISTED
Affimed
AFMD
$4.24M 1.77%
59,500
+470
+0.8% +$31.9K
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.05M 1.7%
500,000
+215,000
+75% +$1.61M
LJPC
25
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.78M 1.58%
+140,000
New +$3.82M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opaleye Management held 60 positions worth $239M, up 18% from $203M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opaleye Management deployed $7.18M of net new capital in Q4 2015, opening 11 new positions and adding to 16 existing holdings. Its largest new stake was Assertio: 5,000 shares worth $5.44M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cempra, Inc., an estimated $4.45M trimmed.

  • Opaleye Management's largest Q4 2015 buy was Assertio: 5,000 shares worth $5.44M.
  • Opaleye Management added most to Sage Therapeutics in Q4 2015, an estimated $3.96M increase.
  • Opaleye Management's biggest Q4 2015 reduction was Cempra, Inc., cutting an estimated $4.45M.
  • Opaleye Management fully exited Chimerix, Inc. in Q4 2015, selling an estimated $11.8M.
  • Opaleye Management's ten largest holdings make up 38% of its $239M portfolio in Q4 2015.
  • Opaleye Management opened 11 new positions and closed 7 in Q4 2015.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $239M.

Based on Opaleye Management's 13F filing for Q4 2015, filed 12 Feb 2016.